U.S. markets closed
  • S&P 500

    4,432.99
    -40.76 (-0.91%)
     
  • Dow 30

    34,584.88
    -166.44 (-0.48%)
     
  • Nasdaq

    15,043.97
    -137.96 (-0.91%)
     
  • Russell 2000

    2,237.57
    +4.66 (+0.21%)
     
  • Crude Oil

    71.99
    -0.62 (-0.85%)
     
  • Gold

    1,752.30
    -4.40 (-0.25%)
     
  • Silver

    22.38
    -0.41 (-1.82%)
     
  • EUR/USD

    1.1730
    -0.0041 (-0.35%)
     
  • 10-Yr Bond

    1.3700
    +0.0390 (+2.93%)
     
  • GBP/USD

    1.3734
    -0.0063 (-0.45%)
     
  • USD/JPY

    109.9600
    +0.2420 (+0.22%)
     
  • BTC-USD

    47,440.84
    -62.32 (-0.13%)
     
  • CMC Crypto 200

    1,200.89
    -24.64 (-2.01%)
     
  • FTSE 100

    6,963.64
    -63.84 (-0.91%)
     
  • Nikkei 225

    30,500.05
    +176.71 (+0.58%)
     

Sanofi to buy mRNA developer for $3.2 billion

·1 min read
Sanofi to buy mRNA developer for $3.2 billion
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Translate Bio Inc. soared 29.8% in premarket trading on Tuesday after Sanofi said it will spend $3.2 billion to buy the developer of messenger RNA (mRNA) technologies. The U.S.-listed shares of Sanofi were down 0.1% in premarket trade. "A fully owned platform allows us to develop additional opportunities in the fast-evolving mRNA space," Sanofi CEO Paul Hudsons said in a statement. Investors are paying much closer attention to mRNA developments since the mRNA COVID-19 vaccines develope